[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 56, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 57, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 46, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.73, "open": 1.74, "dayLow": 1.72, "dayHigh": 1.9, "regularMarketPreviousClose": 1.73, "regularMarketOpen": 1.74, "regularMarketDayLow": 1.72, "regularMarketDayHigh": 1.9, "trailingPE": 2.936508, "forwardPE": -7.115385, "volume": 1751361, "regularMarketVolume": 1751361, "averageVolume": 4364180, "averageVolume10days": 2397890, "averageDailyVolume10Day": 2397890, "bid": 1.36, "ask": 2.25, "bidSize": 100, "askSize": 100, "marketCap": 379144576, "fiftyTwoWeekLow": 1.19, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 38.239494, "fiftyDayAverage": 2.0923, "twoHundredDayAverage": 2.4117, "currency": "USD", "enterpriseValue": 366369600, "profitMargins": -2.29672, "floatShares": 159802573, "sharesOutstanding": 204943008, "sharesShort": 21884340, "sharesShortPriorMonth": 15754592, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.106800005, "heldPercentInsiders": 0.17538, "heldPercentInstitutions": 0.77156997, "shortRatio": 3.66, "shortPercentOfFloat": 0.1409, "impliedSharesOutstanding": 204943008, "bookValue": 0.332, "priceToBook": 5.5722895, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -22772000, "trailingEps": 0.63, "forwardEps": -0.42, "enterpriseToRevenue": 36.951, "enterpriseToEbitda": -4.514, "52WeekChange": -0.017045438, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "messageBoardId": "finmb_665948579", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.85, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.59091, "targetMedianPrice": 7.0, "recommendationMean": 1.36364, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 157688000, "totalCashPerShare": 0.589, "ebitda": -81154000, "totalDebt": 60722000, "quickRatio": 5.375, "currentRatio": 5.507, "totalRevenue": 9915000, "debtToEquity": 68.383, "revenuePerShare": 0.042, "returnOnAssets": -0.27423, "returnOnEquity": -1.1477, "revenueGrowth": -0.623, "grossMargins": 1.0, "operatingMargins": -11.778521, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]